Last reviewed · How we verify
NCT06986486: pCOLA
Liver Transplantation for Unresectable Perihilar Cholangiocarcinoma
trial in Perihilar Cholangiocarcinoma in 8 participants. Currently enrolling.
1 January 2030
Quick facts
| Lead sponsor | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 8 |
| Start date | 1 June 2025 |
| Primary completion | 1 January 2030 |
| Estimated completion | 1 January 2030 |
| Sites | 1 location across Italy |
Conditions studied
- Perihilar Cholangiocarcinoma — all drugs for Perihilar Cholangiocarcinoma →
- Klatskin Tumor — all drugs for Klatskin Tumor →
Sponsor
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano — full company profile →
Who can join
Adults 18 to 70, any sex, with Perihilar Cholangiocarcinoma or Klatskin Tumor. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is multicentric, single-arm, observational, investigator-drive study investigating the efficacy of liver transplantation after successful downstaging/disease control of unresectable perihilar cholangiocarcinoma using chemotherapy +/- immunotherapy and stereotactic body radiation therapy (SBRT).
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06986486
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Perihilar Cholangiocarcinoma
Currently open trials in the same condition.
- NCT06720883 — Robotically Assisted Surgery For Perihilar Cholangiocarcinoma: A Prospective Study · recruiting
- NCT06125769 — LIver TrAnspLantation for Non-resectable Peri-HIlar cholangioCArcinoma (LITALHICA) · NA · recruiting
- NCT05430698 — PD-1 Antibody Plus GEMOX as Postoperative Adjuvant Therapy in Perihilar Cholangiocarcinoma · Phase 2 · recruiting
- NCT04993131 — Liver Transplantation for Non-resectable Perihilar Cholangiocarcinoma · NA · recruiting
Other Fondazione IRCCS Istituto Nazionale dei Tumori, Milano trials
Trials by the same sponsor.
- NCT06799624 — Prognostic Role of molEcular classiFication in Fertility-sparing treAtment of Endometrial canCEr · not yet recruiting
- NCT07253402 — Microbiota-guided Radiotherapy for Head and Neck Cancer · recruiting
- NCT06938724 — Omission of Local Therapies in Women Patients With HER2-positive or Triple-negative Breast Cancer · Phase 2 · recruiting
- NCT06999824 — Revisiting the Concept of Nerve Sparing Radical Hysterectomy · not yet recruiting
- NCT06862934 — Liver Transplantation for Unresectable Intrahepatic Colangiocarcinoma After Sustained Response to Neoadjuvant Treatments · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06986486 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
- Last refreshed: 23 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06986486.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing